The U.S. Food and Drug Administration has qualified the first artificial intelligence tool designed to help doctors assess a ...
Novo Nordisk announced today that Health Canada has issued marketing authorization with conditions [Notice of Compliance with ...
Mayo Clinic researchers have discovered how aging "zombie cells" contribute to inflammation that speeds up a serious form of ...
The FDA has qualified AI-Based Histologic Measurement of NASH, or AIM-NASH — the first AI drug development tool — to assist ...
Mayo Clinic researchers have uncovered how aging "zombie cells" trigger harmful inflammation that accelerates a severe and ...
6don MSN
US FDA approves first AI tool for liver disease trials: How AIM-NASH transforms biopsy reading
NASH, has received FDA approval to revolutionize liver disease drug trials. This innovative technology assists pathologi ...
The FDA has qualified its first artificial intelligence tool to help drug developers evaluate fatty liver disease in their ...
The FDA has qualified the first AI-based tool that can be used in clinical trials involving patients with metabolic ...
MedPage Today brought together three hepatology experts for a virtual roundtable discussion on metabolic ...
ENDRA Life Sciences Inc. (NASDAQ: NDRA) ("ENDRA" or the "Company"), a pioneer in thermo-acoustic biomarker imaging for early ...
The authors provide a useful integrated analytical approach to investigating MASLD focused on diverse multiomic integration methods. The strength of evidence for this new resource is solid, as ...
Metabolic dysfunction-associated steatotic liver disease (MASLD), a spectrum of liver conditions ranging from simple steatosis to steatohepatitis (MASH), fibrosis, and cirrhosis, represents a global ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback